196 related articles for article (PubMed ID: 30765167)
1. Inactivated or damaged? Comparing the effect of inactivation methods on influenza virions to optimize vaccine production.
Herrera-Rodriguez J; Signorazzi A; Holtrop M; de Vries-Idema J; Huckriede A
Vaccine; 2019 Mar; 37(12):1630-1637. PubMed ID: 30765167
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of different inactivation methods for high and low pathogenic avian influenza viruses in egg-fluids for antigen preparation.
Pawar SD; Murtadak VB; Kale SD; Shinde PV; Parkhi SS
J Virol Methods; 2015 Sep; 222():28-33. PubMed ID: 25997377
[TBL] [Abstract][Full Text] [Related]
3. Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity.
Budimir N; Huckriede A; Meijerhof T; Boon L; Gostick E; Price DA; Wilschut J; de Haan A
PLoS One; 2012; 7(1):e30898. PubMed ID: 22303469
[TBL] [Abstract][Full Text] [Related]
4. Examination of the effects of virus inactivation methods on the induction of antibody- and cell-mediated immune responses against whole inactivated H9N2 avian influenza virus vaccines in chickens.
Astill J; Alkie T; Yitbarek A; Taha-Abdelaziz K; Bavananthasivam J; Nagy É; Petrik JJ; Sharif S
Vaccine; 2018 Jun; 36(27):3908-3916. PubMed ID: 29853199
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the beta-propiolactone sensitivity and optimization of inactivation methods for human influenza H3N2 virus.
Sasaki Y; Yoshino N; Sato S; Muraki Y
J Virol Methods; 2016 Sep; 235():105-111. PubMed ID: 27142111
[TBL] [Abstract][Full Text] [Related]
6. Effects of Three Types of Inactivation Agents on the Antibody Response and Immune Protection of Inactivated IHNV Vaccine in Rainbow Trout.
Tang L; Kang H; Duan K; Guo M; Lian G; Wu Y; Li Y; Gao S; Jiang Y; Yin J; Liu M
Viral Immunol; 2016 Sep; 29(7):430-5. PubMed ID: 27548006
[TBL] [Abstract][Full Text] [Related]
7. Effect of viral membrane fusion activity on antibody induction by influenza H5N1 whole inactivated virus vaccine.
Geeraedts F; ter Veer W; Wilschut J; Huckriede A; de Haan A
Vaccine; 2012 Oct; 30(45):6501-7. PubMed ID: 22841974
[TBL] [Abstract][Full Text] [Related]
8. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
[TBL] [Abstract][Full Text] [Related]
9. Hemagglutinin displayed baculovirus protects against highly pathogenic influenza.
Tang XC; Lu HR; Ross TM
Vaccine; 2010 Oct; 28(42):6821-31. PubMed ID: 20727393
[TBL] [Abstract][Full Text] [Related]
10. An Improved Inactivated Influenza Vaccine with Enhanced Cross Protection.
Ni Y; Guo J; Turner D; Tizard I
Front Immunol; 2018; 9():1815. PubMed ID: 30140267
[TBL] [Abstract][Full Text] [Related]
11. Immunologic evaluation of 10 different adjuvants for use in vaccines for chickens against highly pathogenic avian influenza virus.
Lone NA; Spackman E; Kapczynski D
Vaccine; 2017 Jun; 35(26):3401-3408. PubMed ID: 28511853
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of SARS-CoV-2 by β-propiolactone causes aggregation of viral particles and loss of antigenic potential.
Gupta D; Parthasarathy H; Sah V; Tandel D; Vedagiri D; Reddy S; Harshan KH
Virus Res; 2021 Nov; 305():198555. PubMed ID: 34487766
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of different methods of inactivation of Newcastle disease virus and avian influenza virus in egg fluids and serum.
King DJ
Avian Dis; 1991; 35(3):505-14. PubMed ID: 1835374
[TBL] [Abstract][Full Text] [Related]
14. A novel approach for preparation of the antisera reagent for potency determination of inactivated H7N9 influenza vaccines.
Schmeisser F; Jing X; Joshi M; Vasudevan A; Soto J; Li X; Choudhary A; Baichoo N; Resnick J; Ye Z; McCormick W; Weir JP
Influenza Other Respir Viruses; 2016 Mar; 10(2):134-40. PubMed ID: 26616263
[TBL] [Abstract][Full Text] [Related]
15. [Technological approaches to development of whole-virion inactivated vaccine from recombinant strain against A/H5N1 influenza in the Republic of Kazakhstan].
Kydyrbaev ZhK; Mamadaliev SM; Asanzhanova NN; Tabynov KK; Ryskel'dinova ShZh; Cherviakova OV; Sandybaev NT; Khaĭrullin BM; Kiselev OI
Zh Mikrobiol Epidemiol Immunobiol; 2012; (5):54-9. PubMed ID: 23163037
[TBL] [Abstract][Full Text] [Related]
16. Inactivation methods for whole influenza vaccine production.
Sabbaghi A; Miri SM; Keshavarz M; Zargar M; Ghaemi A
Rev Med Virol; 2019 Nov; 29(6):e2074. PubMed ID: 31334909
[TBL] [Abstract][Full Text] [Related]
17. Influenza H5 virus escape mutants: immune protection and antibody production in mice.
Smirnov YA; Gitelman AK; Govorkova EA; Lipatov AS; Kaverin NV
Virus Res; 2004 Feb; 99(2):205-8. PubMed ID: 14749187
[TBL] [Abstract][Full Text] [Related]
18. Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?
Tamura S; Ainai A; Suzuki T; Kurata T; Hasegawa H
Jpn J Infect Dis; 2016; 69(3):165-79. PubMed ID: 27212584
[TBL] [Abstract][Full Text] [Related]
19. Cross-Protection by Inactivated H5 Prepandemic Vaccine Seed Strains against Diverse Goose/Guangdong Lineage H5N1 Highly Pathogenic Avian Influenza Viruses.
Criado MF; Sá E Silva M; Lee DH; Salge CAL; Spackman E; Donis R; Wan XF; Swayne DE
J Virol; 2020 Nov; 94(24):. PubMed ID: 32999029
[TBL] [Abstract][Full Text] [Related]
20. The influence of the inactivating agent on the antigen content of inactivated Newcastle disease vaccines assessed by the in vitro potency test.
Jagt HJ; Bekkers ML; van Bommel SA; van der Marel P; Schrier CC
Biologicals; 2010 Jan; 38(1):128-34. PubMed ID: 19716316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
